Dataset Information

Serum-deprivation leads to activation-like changes in primary microglia and BV-2 cells but not astrocytes.

ABSTRACT: The aim of the present study was to determine the effect of serum deprivation on primary microglia, BV-2 cells and primary astrocytes. Cell morphology combined with the expression of phospho-(p-)38 and p-extracellular signal-regulated kinase (ERK) were assessed. Serum deprivation resulted in various alterations in the three cell cultures. Primary microglia and BV-2 cells exhibited alterations indicative of activation under serum treatment, as well as lipopolysaccharide (LPS) treatment. However, astrocytes did not react as fast. Regarding morphology, the processes present on the primary microglia and BV-2 cells became shorter and the cell bodies became larger, and more transparent vesicles were observed within the cell bodies, which indicated their increased phagocytic ability. At the protein level, p-p38 expression increased quickly within 1 h in the primary microglia culture in response to LPS treatment. Furthermore, the expression levels of p-p38 and p-ERK were elevated in both primary microglia and BV-2 cells under serum deprivation, as well as under LPS treatment, which was not observed in the primary astrocytes. These results suggest that serum deprivation may result in similar changes to cell morphology and the expression levels of p-p38 and p-ERK as LPS treatment in primary microglia and BV-2 cells. These observations suggest that primary microglia and BV-2 cells may become activated under serum deprivation, at least to a certain degree.

SUBMITTER: Yao Y

PROVIDER: S-EPMC7506474 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Serum-deprivation leads to activation-like changes in primary microglia and BV-2 cells but not astrocytes.

Yao Yao Y Fu Kai-Yuan KY

Biomedical reports 20200914 5

The aim of the present study was to determine the effect of serum deprivation on primary microglia, BV-2 cells and primary astrocytes. Cell morphology combined with the expression of phospho-(p-)38 and p-extracellular signal-regulated kinase (ERK) were assessed. Serum deprivation resulted in various alterations in the three cell cultures. Primary microglia and BV-2 cells exhibited alterations indicative of activation under serum treatment, as well as lipopolysaccharide (LPS) treatment. However, ...[more]

PMID: 32974017

Similar Datasets

Project description:Background: Naltrexone is an opioid receptor antagonist commonly used to treat opioid and alcohol dependence. The use of low dose naltrexone (LDN) was found to have anti-inflammatory properties for treatment of diseases such as fibromyalgia, Crohn's disease, multiple sclerosis and regional pain syndromes. Related to its anti-neuroinflammatory properties, the mechanism of action is possibly mediated via Toll-like receptor 4 antagonism, which is widely expressed on microglial cells. The aim of the present study was to assess the immunometabolic effects of naltrexone on microglia cells in in vitro conditions. All experiments were performed in the BV-2 microglial cell line. The cells were treated with naltrexone at 100 μM concentrations corresponding to low dose for 24 h. Cell viability was assessed for every drug dose. To induce additional activation, the cells were pretreated with LPS and IFN-γ. Immunofluorescence was used to analyse the classical microglial activation markers iNOS and CD206, while Seahorse was used for real-time cellular metabolic assessments. mTOR activity measured over the expression of a major direct downstream target S6K was assessed using western blot. LDN induced a shift from highly activated pro-inflammatory phenotype (iNOShighCD206low) to quiescent anti-inflammatory M2 phenotype (iNOSlowCD206high) in BV-2 microglia cells. Changes in the inflammatory profile were accompanied by cellular metabolic switching based on the transition from high glycolysis to mitochondrial oxidative phosphorylation (OXPHOS). LDN-treated cells were able to maintain a metabolically suppressive phenotype by supporting OXPHOS with high oxygen consumption, and also maintain a lower energetic state due to lower lactate production. The metabolic shift induced by transition from glycolysis to mitochondrial oxidative metabolism was more prominent in cells pretreated with immunometabolic modulators such as LPS and IFN-γ. In a dose-dependent manner, naltrexone also modulated mTOR/S6K expression, which underlies the cell metabolic phenotype regulating microglia immune properties and adaptation. By modulating the phenotypic features by metabolic switching of activated microglia, naltrexone was found to be an effective and powerful tool for immunometabolic reprogramming and could be a promising novel treatment for various neuroinflammatory conditions.

Project description:BACKGROUND:As the primary immune response cell in the central nervous system, microglia constantly monitor the microenvironment and respond rapidly to stress, infection, and injury, making them important modulators of neuroinflammatory responses. In diseases such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, and human immunodeficiency virus-induced dementia, activation of microglia precedes astrogliosis and overt neuronal loss. Although microgliosis is implicated in manganese (Mn) neurotoxicity, the role of microglia and glial crosstalk in Mn-induced neurodegeneration is poorly understood. METHODS:Experiments utilized immunopurified murine microglia and astrocytes using column-free magnetic separation. The effect of Mn on microglia was investigated using gene expression analysis, Mn uptake measurements, protein production, and changes in morphology. Additionally, gene expression analysis was used to determine the effect Mn-treated microglia had on inflammatory responses in Mn-exposed astrocytes. RESULTS:Immunofluorescence and flow cytometric analysis of immunopurified microglia and astrocytes indicated cultures were 97 and 90% pure, respectively. Mn treatment in microglia resulted in a dose-dependent increase in pro-inflammatory gene expression, transition to a mixed M1/M2 phenotype, and a de-ramified morphology. Conditioned media from Mn-exposed microglia (MCM) dramatically enhanced expression of mRNA for Tnf, Il-1?, Il-6, Ccl2, and Ccl5 in astrocytes, as did exposure to Mn in the presence of co-cultured microglia. MCM had increased levels of cytokines and chemokines including IL-6, TNF, CCL2, and CCL5. Pharmacological inhibition of NF-?B in microglia using Bay 11-7082 completely blocked microglial-induced astrocyte activation, whereas siRNA knockdown of Tnf in primary microglia only partially inhibited neuroinflammatory responses in astrocytes. CONCLUSIONS:These results provide evidence that NF-?B signaling in microglia plays an essential role in inflammatory responses in Mn toxicity by regulating cytokines and chemokines that amplify the activation of astrocytes.

Dataset Information

Serum-deprivation leads to activation-like changes in primary microglia and BV-2 cells but not astrocytes.

Publications

Serum-deprivation leads to activation-like changes in primary microglia and BV-2 cells but not astrocytes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets